MerckVaccines.com | Official Website for Health Care Professionals
WEBAug 16, 2024 · MerckVaccines is a site for health care professionals to find information about Merck's vaccine portfolio, as well as vaccine tools and resources.
Vaccines - Merck.com
WEBWe've been discovering, developing, supplying and delivering vaccines to help prevent disease around the world for over 130 years. It is no secret that inventing and developing vaccines is complex, time intensive and carries no guarantees.
Contact Us | MerckVaccines.com Customer Service - global
WEBContact Merck Vaccines customer service by using the online contact form, calling the Merck Vaccine Customer Contact Center, or use the Callback service to speak to a Vaccine Account Representative.
VARIVAX® (Varicella Virus Vaccine Live) | Official Site
WEBVARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age or older. Selected Safety Information for VARIVAX.
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent ... - Merck
WEBJun 17, 2024 · CAPVAXIVE is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15 …
WEBJun 22, 2022 · U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children. Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four-dose series and superior immune responses for ...
FDA approves Merck vaccine designed to protect adults from
WEBThe Food and Drug Administration on Monday approved Merck's new vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection...
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, …
WEBGARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
WEBJun 18, 2024 · The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against 21 types of the bacteria that causes pneumococcal disease. The vaccine, cleared for use in adults 18 …
Merck Announces V116, an Investigational, 21-valent …
WEBJul 27, 2023 · Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials. Topline results demonstrated V116 elicited positive immune responses in both vaccine-naïve and vaccine-experienced adult patient populations. The 21 serotypes ...